Gilead Sciences Inc

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc’s Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The approval does not include...

News Hour: Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class...